| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 373 | 2024 | 10895 | 25.410 |
Why?
|
| Stroke Volume | 203 | 2024 | 5006 | 11.310 |
Why?
|
| Angiotensin Receptor Antagonists | 56 | 2023 | 923 | 7.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 76 | 2024 | 11726 | 5.420 |
Why?
|
| Cardiovascular Diseases | 68 | 2023 | 15160 | 4.720 |
Why?
|
| Hospitalization | 106 | 2024 | 10259 | 4.690 |
Why?
|
| Ventricular Function, Left | 71 | 2024 | 3666 | 4.560 |
Why?
|
| Tetrazoles | 34 | 2023 | 835 | 4.210 |
Why?
|
| Ventricular Dysfunction, Left | 29 | 2024 | 2073 | 4.130 |
Why?
|
| Renal Insufficiency, Chronic | 27 | 2023 | 2200 | 3.820 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 36 | 2024 | 1516 | 3.460 |
Why?
|
| Biphenyl Compounds | 35 | 2023 | 913 | 3.270 |
Why?
|
| Adenosine Monophosphate | 9 | 2019 | 275 | 3.040 |
Why?
|
| Hypoglycemic Agents | 29 | 2024 | 2873 | 2.910 |
Why?
|
| Ticlopidine | 14 | 2017 | 899 | 2.640 |
Why?
|
| Clinical Trials as Topic | 39 | 2024 | 7914 | 2.640 |
Why?
|
| Platelet Aggregation Inhibitors | 26 | 2021 | 3070 | 2.630 |
Why?
|
| Benzhydryl Compounds | 31 | 2024 | 845 | 2.600 |
Why?
|
| Drug Combinations | 34 | 2023 | 1958 | 2.580 |
Why?
|
| Glucosides | 23 | 2024 | 451 | 2.570 |
Why?
|
| Diuretics | 16 | 2023 | 591 | 2.520 |
Why?
|
| Humans | 601 | 2024 | 744366 | 2.470 |
Why?
|
| Diabetes Mellitus | 24 | 2023 | 5749 | 2.460 |
Why?
|
| Cardiology | 14 | 2021 | 1668 | 2.180 |
Why?
|
| Benzazepines | 14 | 2019 | 326 | 2.070 |
Why?
|
| Natriuretic Peptides | 15 | 2023 | 150 | 2.030 |
Why?
|
| Cardiovascular Agents | 14 | 2022 | 850 | 2.000 |
Why?
|
| Neprilysin | 15 | 2023 | 439 | 1.960 |
Why?
|
| Myocardial Infarction | 40 | 2024 | 11718 | 1.920 |
Why?
|
| United States Food and Drug Administration | 11 | 2021 | 1584 | 1.900 |
Why?
|
| Proton Pump Inhibitors | 5 | 2016 | 526 | 1.900 |
Why?
|
| Renin-Angiotensin System | 14 | 2024 | 758 | 1.870 |
Why?
|
| Patient Readmission | 27 | 2021 | 3116 | 1.830 |
Why?
|
| Natriuretic Peptide, Brain | 28 | 2024 | 1572 | 1.800 |
Why?
|
| Acute Coronary Syndrome | 17 | 2024 | 2337 | 1.780 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 3135 | 1.770 |
Why?
|
| Pneumonia, Viral | 10 | 2020 | 3242 | 1.760 |
Why?
|
| Aspirin | 16 | 2021 | 3283 | 1.730 |
Why?
|
| Registries | 30 | 2023 | 8091 | 1.720 |
Why?
|
| Atrial Flutter | 6 | 2022 | 263 | 1.640 |
Why?
|
| Adrenergic beta-Antagonists | 11 | 2023 | 1240 | 1.600 |
Why?
|
| Inpatients | 14 | 2023 | 2518 | 1.590 |
Why?
|
| Glomerular Filtration Rate | 17 | 2024 | 2166 | 1.580 |
Why?
|
| Atrial Fibrillation | 23 | 2023 | 5035 | 1.560 |
Why?
|
| Aged | 192 | 2024 | 163288 | 1.540 |
Why?
|
| Cardiotonic Agents | 11 | 2020 | 535 | 1.530 |
Why?
|
| Foramen Ovale, Patent | 3 | 2018 | 223 | 1.530 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2021 | 1541 | 1.520 |
Why?
|
| Antihypertensive Agents | 18 | 2023 | 2047 | 1.480 |
Why?
|
| United States | 111 | 2024 | 69872 | 1.460 |
Why?
|
| Metabolic Diseases | 3 | 2022 | 658 | 1.460 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 8 | 2019 | 362 | 1.440 |
Why?
|
| Defibrillators, Implantable | 8 | 2022 | 1440 | 1.420 |
Why?
|
| Drug Utilization | 8 | 2021 | 1183 | 1.370 |
Why?
|
| Angioedema | 2 | 2020 | 187 | 1.320 |
Why?
|
| Coronary Thrombosis | 5 | 2016 | 495 | 1.320 |
Why?
|
| Randomized Controlled Trials as Topic | 39 | 2024 | 9955 | 1.310 |
Why?
|
| Male | 233 | 2024 | 350115 | 1.290 |
Why?
|
| Spironolactone | 9 | 2022 | 382 | 1.270 |
Why?
|
| Hypertension | 18 | 2023 | 8479 | 1.270 |
Why?
|
| Anticoagulants | 16 | 2023 | 4600 | 1.260 |
Why?
|
| Drug Labeling | 2 | 2021 | 233 | 1.260 |
Why?
|
| Diabetic Nephropathies | 3 | 2023 | 984 | 1.230 |
Why?
|
| Female | 233 | 2024 | 380193 | 1.230 |
Why?
|
| Pandemics | 17 | 2023 | 8385 | 1.220 |
Why?
|
| Treatment Outcome | 91 | 2023 | 63107 | 1.220 |
Why?
|
| Disease Management | 12 | 2019 | 2460 | 1.210 |
Why?
|
| Angiotensins | 8 | 2024 | 151 | 1.170 |
Why?
|
| Specialization | 3 | 2021 | 776 | 1.170 |
Why?
|
| Kidney | 21 | 2023 | 7184 | 1.160 |
Why?
|
| Digoxin | 6 | 2022 | 250 | 1.150 |
Why?
|
| Platelet Aggregation | 6 | 2016 | 798 | 1.130 |
Why?
|
| Middle Aged | 155 | 2023 | 213390 | 1.110 |
Why?
|
| Prognosis | 78 | 2024 | 29060 | 1.110 |
Why?
|
| Blood Pressure | 22 | 2023 | 8551 | 1.090 |
Why?
|
| Patient Discharge | 21 | 2023 | 3318 | 1.080 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2020 | 293 | 1.050 |
Why?
|
| Omeprazole | 2 | 2016 | 112 | 1.050 |
Why?
|
| Troponin T | 8 | 2023 | 754 | 1.040 |
Why?
|
| Receptors, Purinergic P2Y12 | 2 | 2016 | 132 | 1.020 |
Why?
|
| Metformin | 2 | 2023 | 836 | 1.000 |
Why?
|
| Risk Assessment | 41 | 2022 | 23336 | 1.000 |
Why?
|
| Coronary Artery Disease | 13 | 2019 | 6486 | 0.990 |
Why?
|
| Drug Approval | 5 | 2021 | 742 | 0.990 |
Why?
|
| Heart Transplantation | 7 | 2023 | 3112 | 0.990 |
Why?
|
| Renal Insufficiency | 7 | 2019 | 804 | 0.970 |
Why?
|
| Heart Diseases | 6 | 2023 | 2789 | 0.970 |
Why?
|
| Symporters | 3 | 2022 | 361 | 0.960 |
Why?
|
| Blood Platelets | 9 | 2016 | 2509 | 0.950 |
Why?
|
| Shock, Cardiogenic | 3 | 2019 | 688 | 0.940 |
Why?
|
| Double-Blind Method | 30 | 2023 | 12025 | 0.940 |
Why?
|
| Cause of Death | 16 | 2022 | 3582 | 0.930 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2023 | 581 | 0.920 |
Why?
|
| Practice Guidelines as Topic | 13 | 2021 | 7282 | 0.910 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 1537 | 0.900 |
Why?
|
| Hospitals | 9 | 2021 | 3954 | 0.900 |
Why?
|
| Information Dissemination | 4 | 2021 | 1099 | 0.880 |
Why?
|
| Risk Factors | 74 | 2023 | 72296 | 0.880 |
Why?
|
| Medicare | 22 | 2024 | 6566 | 0.870 |
Why?
|
| Research Design | 13 | 2023 | 5984 | 0.870 |
Why?
|
| Atherosclerosis | 12 | 2023 | 3444 | 0.860 |
Why?
|
| Patient Selection | 15 | 2022 | 4216 | 0.860 |
Why?
|
| Hospital Mortality | 28 | 2022 | 5316 | 0.850 |
Why?
|
| Stroke | 15 | 2023 | 9981 | 0.850 |
Why?
|
| International Classification of Diseases | 5 | 2021 | 867 | 0.850 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2023 | 1421 | 0.840 |
Why?
|
| Pharmacy | 1 | 2023 | 91 | 0.830 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2017 | 1131 | 0.820 |
Why?
|
| Pharmacies | 1 | 2023 | 150 | 0.820 |
Why?
|
| Death, Sudden | 3 | 2019 | 302 | 0.820 |
Why?
|
| Albuminuria | 4 | 2023 | 681 | 0.810 |
Why?
|
| Drug-Eluting Stents | 5 | 2017 | 753 | 0.800 |
Why?
|
| Sodium | 13 | 2023 | 1622 | 0.800 |
Why?
|
| Peptide Fragments | 19 | 2024 | 5096 | 0.790 |
Why?
|
| Fumarates | 3 | 2018 | 132 | 0.770 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 1637 | 0.770 |
Why?
|
| Aged, 80 and over | 58 | 2023 | 57776 | 0.770 |
Why?
|
| Kidney Diseases | 2 | 2023 | 2148 | 0.760 |
Why?
|
| Health Status | 7 | 2023 | 4034 | 0.750 |
Why?
|
| Heart-Assist Devices | 5 | 2022 | 1195 | 0.740 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2017 | 1873 | 0.740 |
Why?
|
| Anterior Wall Myocardial Infarction | 2 | 2021 | 45 | 0.740 |
Why?
|
| Medicaid | 8 | 2021 | 2737 | 0.730 |
Why?
|
| Hyperkalemia | 2 | 2022 | 218 | 0.730 |
Why?
|
| Drug Therapy, Combination | 14 | 2021 | 6489 | 0.730 |
Why?
|
| Follow-Up Studies | 39 | 2022 | 39052 | 0.720 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2020 | 451 | 0.720 |
Why?
|
| Comorbidity | 26 | 2023 | 10388 | 0.720 |
Why?
|
| Endpoint Determination | 7 | 2022 | 601 | 0.720 |
Why?
|
| Blood Pressure Determination | 3 | 2020 | 633 | 0.710 |
Why?
|
| Amides | 4 | 2021 | 459 | 0.700 |
Why?
|
| Time Factors | 38 | 2021 | 40075 | 0.700 |
Why?
|
| Renin | 2 | 2021 | 642 | 0.700 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2021 | 3255 | 0.690 |
Why?
|
| Cardiomyopathies | 4 | 2023 | 1912 | 0.680 |
Why?
|
| Medicare Part D | 5 | 2021 | 328 | 0.680 |
Why?
|
| Influenza Vaccines | 5 | 2023 | 738 | 0.660 |
Why?
|
| Iliac Artery | 1 | 2020 | 364 | 0.650 |
Why?
|
| Epirubicin | 1 | 2018 | 80 | 0.650 |
Why?
|
| Economics, Hospital | 4 | 2020 | 213 | 0.650 |
Why?
|
| Stents | 5 | 2017 | 3282 | 0.650 |
Why?
|
| Cardiovascular System | 3 | 2022 | 831 | 0.650 |
Why?
|
| Troponin | 3 | 2017 | 524 | 0.640 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 365 | 0.630 |
Why?
|
| Postoperative Complications | 8 | 2020 | 15297 | 0.630 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2017 | 641 | 0.620 |
Why?
|
| Osmolar Concentration | 2 | 2016 | 683 | 0.610 |
Why?
|
| Evidence-Based Medicine | 5 | 2020 | 3611 | 0.610 |
Why?
|
| Secondary Prevention | 4 | 2019 | 1530 | 0.610 |
Why?
|
| Funnel Chest | 1 | 2018 | 71 | 0.610 |
Why?
|
| Hyperlipidemias | 2 | 2014 | 789 | 0.610 |
Why?
|
| Medicare Part C | 1 | 2022 | 296 | 0.610 |
Why?
|
| Interdisciplinary Communication | 3 | 2020 | 950 | 0.610 |
Why?
|
| Drug Discovery | 2 | 2016 | 1058 | 0.600 |
Why?
|
| Nurse Clinicians | 1 | 2017 | 31 | 0.600 |
Why?
|
| Prescription Drugs | 3 | 2021 | 595 | 0.600 |
Why?
|
| Surgical Instruments | 1 | 2020 | 395 | 0.590 |
Why?
|
| Heart Failure, Diastolic | 4 | 2023 | 69 | 0.590 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2018 | 841 | 0.590 |
Why?
|
| Prosthesis Implantation | 3 | 2020 | 642 | 0.590 |
Why?
|
| Warfarin | 2 | 2017 | 1497 | 0.580 |
Why?
|
| Quality of Life | 19 | 2023 | 12802 | 0.580 |
Why?
|
| Health Expenditures | 6 | 2022 | 2349 | 0.570 |
Why?
|
| Glucose | 12 | 2023 | 4398 | 0.570 |
Why?
|
| Blood Glucose | 9 | 2022 | 6254 | 0.570 |
Why?
|
| Meta-Analysis as Topic | 2 | 2021 | 1342 | 0.560 |
Why?
|
| Tissue Donors | 4 | 2023 | 2241 | 0.560 |
Why?
|
| Adenosine | 3 | 2017 | 825 | 0.560 |
Why?
|
| Hemoptysis | 1 | 2017 | 155 | 0.560 |
Why?
|
| Retrospective Studies | 49 | 2023 | 77460 | 0.560 |
Why?
|
| Prediabetic State | 4 | 2022 | 499 | 0.560 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2016 | 40 | 0.550 |
Why?
|
| Aftercare | 7 | 2023 | 870 | 0.550 |
Why?
|
| Dinucleoside Phosphates | 1 | 2016 | 74 | 0.540 |
Why?
|
| Incretins | 3 | 2021 | 88 | 0.540 |
Why?
|
| Venous Thromboembolism | 4 | 2023 | 1671 | 0.540 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1070 | 0.530 |
Why?
|
| Eye Diseases | 1 | 2021 | 669 | 0.530 |
Why?
|
| Hemorrhage | 8 | 2021 | 3461 | 0.520 |
Why?
|
| Syncope | 1 | 2018 | 429 | 0.520 |
Why?
|
| Heart Valve Diseases | 3 | 2012 | 1074 | 0.520 |
Why?
|
| Leg | 1 | 2020 | 1116 | 0.510 |
Why?
|
| Financing, Organized | 1 | 2016 | 202 | 0.510 |
Why?
|
| Equipment Failure | 1 | 2017 | 578 | 0.510 |
Why?
|
| Influenza, Human | 5 | 2023 | 1479 | 0.510 |
Why?
|
| Morbidity | 6 | 2021 | 1768 | 0.510 |
Why?
|
| Fellowships and Scholarships | 3 | 2020 | 1078 | 0.510 |
Why?
|
| Periodicals as Topic | 6 | 2022 | 1431 | 0.500 |
Why?
|
| Physician Assistants | 1 | 2017 | 192 | 0.500 |
Why?
|
| Thrombectomy | 2 | 2020 | 680 | 0.490 |
Why?
|
| Munchausen Syndrome | 1 | 2014 | 20 | 0.490 |
Why?
|
| Furosemide | 4 | 2023 | 167 | 0.490 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 2148 | 0.480 |
Why?
|
| Models, Educational | 2 | 2014 | 377 | 0.480 |
Why?
|
| Hepatic Encephalopathy | 1 | 2015 | 139 | 0.480 |
Why?
|
| Prospective Studies | 35 | 2023 | 53290 | 0.480 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 412 | 0.480 |
Why?
|
| Cohort Studies | 29 | 2023 | 40559 | 0.480 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 522 | 0.470 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 269 | 0.470 |
Why?
|
| Physicians | 3 | 2022 | 4567 | 0.470 |
Why?
|
| Ocular Motility Disorders | 1 | 2015 | 135 | 0.470 |
Why?
|
| Vaccination | 7 | 2023 | 3279 | 0.470 |
Why?
|
| Diuresis | 1 | 2013 | 116 | 0.470 |
Why?
|
| Heparin | 2 | 2020 | 1637 | 0.460 |
Why?
|
| Thrombosis | 4 | 2020 | 2968 | 0.460 |
Why?
|
| Sodium Chloride | 1 | 2016 | 625 | 0.460 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 793 | 0.460 |
Why?
|
| Echocardiography | 11 | 2022 | 5099 | 0.460 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 662 | 0.460 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2014 | 629 | 0.460 |
Why?
|
| Incidence | 19 | 2023 | 20952 | 0.450 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2014 | 113 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2019 | 10943 | 0.450 |
Why?
|
| Length of Stay | 6 | 2021 | 6311 | 0.450 |
Why?
|
| Coronary Occlusion | 1 | 2016 | 304 | 0.450 |
Why?
|
| Heart Neoplasms | 1 | 2016 | 374 | 0.450 |
Why?
|
| Biomedical Technology | 1 | 2015 | 220 | 0.440 |
Why?
|
| Bumetanide | 1 | 2013 | 95 | 0.440 |
Why?
|
| Monitoring, Physiologic | 3 | 2017 | 1739 | 0.440 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2020 | 3537 | 0.440 |
Why?
|
| Mineralocorticoids | 2 | 2023 | 38 | 0.440 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 512 | 0.440 |
Why?
|
| Sodium-Glucose Transporter 2 | 3 | 2023 | 85 | 0.440 |
Why?
|
| Proportional Hazards Models | 19 | 2023 | 12356 | 0.440 |
Why?
|
| Medicine | 1 | 2021 | 946 | 0.430 |
Why?
|
| Hypotension | 3 | 2015 | 884 | 0.430 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.420 |
Why?
|
| Age Distribution | 6 | 2021 | 2902 | 0.420 |
Why?
|
| Diabetes Complications | 1 | 2019 | 1359 | 0.420 |
Why?
|
| Longevity | 1 | 2020 | 1071 | 0.420 |
Why?
|
| Exercise Test | 2 | 2023 | 2073 | 0.420 |
Why?
|
| Calcinosis | 3 | 2020 | 1499 | 0.410 |
Why?
|
| Sex Factors | 15 | 2021 | 10400 | 0.410 |
Why?
|
| Enalapril | 4 | 2022 | 327 | 0.410 |
Why?
|
| Survival Rate | 19 | 2021 | 12788 | 0.410 |
Why?
|
| School Health Services | 1 | 2015 | 375 | 0.410 |
Why?
|
| Lung Transplantation | 1 | 2020 | 1155 | 0.410 |
Why?
|
| Coronary Artery Bypass | 6 | 2021 | 2288 | 0.400 |
Why?
|
| Myocardium | 4 | 2020 | 4772 | 0.390 |
Why?
|
| Heart Failure, Systolic | 2 | 2023 | 126 | 0.390 |
Why?
|
| Safety | 1 | 2016 | 1186 | 0.380 |
Why?
|
| Neoplasms | 7 | 2023 | 21696 | 0.380 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 896 | 0.380 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 2158 | 0.370 |
Why?
|
| Athletes | 1 | 2018 | 1093 | 0.370 |
Why?
|
| Disease Progression | 13 | 2022 | 13286 | 0.370 |
Why?
|
| Drug Design | 2 | 2015 | 1076 | 0.370 |
Why?
|
| Europe | 8 | 2020 | 3338 | 0.370 |
Why?
|
| Diabetic Cardiomyopathies | 2 | 2021 | 95 | 0.370 |
Why?
|
| Vasodilator Agents | 4 | 2023 | 976 | 0.370 |
Why?
|
| Uric Acid | 2 | 2023 | 766 | 0.360 |
Why?
|
| Magnesium | 1 | 2013 | 813 | 0.360 |
Why?
|
| Government Programs | 2 | 2023 | 275 | 0.350 |
Why?
|
| Body Mass Index | 7 | 2022 | 12721 | 0.350 |
Why?
|
| Curriculum | 2 | 2022 | 3605 | 0.350 |
Why?
|
| Aortic Valve Stenosis | 3 | 2023 | 1965 | 0.350 |
Why?
|
| Nutrition Surveys | 5 | 2023 | 1660 | 0.350 |
Why?
|
| Ischemic Attack, Transient | 3 | 2021 | 935 | 0.350 |
Why?
|
| Cystatin C | 3 | 2023 | 250 | 0.350 |
Why?
|
| Troponin I | 4 | 2024 | 619 | 0.340 |
Why?
|
| Mortality | 6 | 2021 | 2864 | 0.340 |
Why?
|
| Heart | 3 | 2022 | 4464 | 0.340 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2708 | 0.340 |
Why?
|
| Hemodynamics | 4 | 2015 | 4196 | 0.340 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 1912 | 0.330 |
Why?
|
| Platelet Activation | 4 | 2015 | 674 | 0.330 |
Why?
|
| Self-Injurious Behavior | 1 | 2014 | 464 | 0.330 |
Why?
|
| Drugs, Generic | 3 | 2023 | 421 | 0.320 |
Why?
|
| Health Promotion | 2 | 2023 | 2205 | 0.320 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 2291 | 0.320 |
Why?
|
| Journal Impact Factor | 3 | 2020 | 156 | 0.320 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2021 | 264 | 0.320 |
Why?
|
| Creatinine | 8 | 2024 | 1919 | 0.320 |
Why?
|
| Electrocardiography | 10 | 2020 | 6442 | 0.320 |
Why?
|
| Telemedicine | 2 | 2023 | 2872 | 0.320 |
Why?
|
| Patient Care Management | 3 | 2021 | 306 | 0.320 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 1170 | 0.310 |
Why?
|
| Adult | 46 | 2024 | 214052 | 0.310 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 1273 | 0.310 |
Why?
|
| Heart Arrest | 1 | 2018 | 1470 | 0.310 |
Why?
|
| Overweight | 3 | 2023 | 2371 | 0.300 |
Why?
|
| Prevalence | 15 | 2023 | 15221 | 0.300 |
Why?
|
| Severity of Illness Index | 14 | 2021 | 15535 | 0.300 |
Why?
|
| Authorship | 2 | 2020 | 271 | 0.300 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2023 | 3047 | 0.300 |
Why?
|
| Multicenter Studies as Topic | 5 | 2019 | 1677 | 0.290 |
Why?
|
| Kansas | 2 | 2023 | 39 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2016 | 6539 | 0.290 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1783 | 0.280 |
Why?
|
| Electronic Health Records | 4 | 2023 | 4468 | 0.280 |
Why?
|
| Quality Improvement | 2 | 2021 | 3749 | 0.280 |
Why?
|
| Intraoperative Period | 2 | 2017 | 520 | 0.270 |
Why?
|
| Myocardial Revascularization | 4 | 2020 | 841 | 0.270 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 1391 | 0.260 |
Why?
|
| Leukocytes | 1 | 2013 | 2045 | 0.260 |
Why?
|
| Chronic Disease | 11 | 2023 | 9145 | 0.260 |
Why?
|
| Acute Disease | 9 | 2021 | 7147 | 0.250 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2023 | 135 | 0.250 |
Why?
|
| Dyspnea | 4 | 2023 | 1303 | 0.250 |
Why?
|
| Coronary Angiography | 6 | 2021 | 4576 | 0.250 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2023 | 340 | 0.250 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2020 | 430 | 0.250 |
Why?
|
| Injections, Intravenous | 2 | 2017 | 1420 | 0.240 |
Why?
|
| Sex Distribution | 5 | 2021 | 2297 | 0.240 |
Why?
|
| Particulate Matter | 1 | 2016 | 2529 | 0.240 |
Why?
|
| Potassium | 2 | 2021 | 1336 | 0.240 |
Why?
|
| Patient Care Team | 3 | 2023 | 2531 | 0.240 |
Why?
|
| Veterans | 3 | 2022 | 2519 | 0.240 |
Why?
|
| Dihydropyridines | 1 | 2023 | 67 | 0.230 |
Why?
|
| Physicians, Women | 2 | 2020 | 486 | 0.230 |
Why?
|
| Life Style | 1 | 2015 | 3835 | 0.230 |
Why?
|
| Thoracic Surgery | 2 | 2020 | 719 | 0.230 |
Why?
|
| Palliative Care | 1 | 2018 | 3493 | 0.230 |
Why?
|
| Health Behavior | 1 | 2015 | 2635 | 0.230 |
Why?
|
| Preoperative Care | 2 | 2012 | 2251 | 0.230 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 5135 | 0.230 |
Why?
|
| Age Factors | 12 | 2021 | 18373 | 0.230 |
Why?
|
| Lipids | 1 | 2014 | 3307 | 0.230 |
Why?
|
| Freedom | 1 | 2023 | 69 | 0.220 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2021 | 176 | 0.220 |
Why?
|
| Therapies, Investigational | 2 | 2014 | 112 | 0.220 |
Why?
|
| Natriuretic Agents | 2 | 2019 | 25 | 0.220 |
Why?
|
| Cross-Sectional Studies | 12 | 2023 | 25039 | 0.220 |
Why?
|
| Erythrocyte Indices | 1 | 2023 | 146 | 0.220 |
Why?
|
| Healthcare Disparities | 5 | 2022 | 3154 | 0.220 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 2736 | 0.210 |
Why?
|
| Fatal Outcome | 3 | 2017 | 1851 | 0.210 |
Why?
|
| Obesity | 9 | 2023 | 12746 | 0.210 |
Why?
|
| Publishing | 2 | 2020 | 833 | 0.210 |
Why?
|
| Prescriptions | 2 | 2023 | 387 | 0.210 |
Why?
|
| Decision Making | 3 | 2022 | 3888 | 0.210 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 2274 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 3 | 2020 | 2716 | 0.210 |
Why?
|
| Bibliometrics | 3 | 2020 | 339 | 0.210 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2023 | 164 | 0.210 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2020 | 857 | 0.200 |
Why?
|
| Fibric Acids | 1 | 2021 | 25 | 0.200 |
Why?
|
| Atrial Function, Left | 2 | 2020 | 173 | 0.200 |
Why?
|
| Cooperative Behavior | 2 | 2020 | 1504 | 0.200 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2021 | 54 | 0.200 |
Why?
|
| Peripheral Arterial Disease | 2 | 2023 | 1188 | 0.200 |
Why?
|
| Ventricular Remodeling | 3 | 2022 | 1223 | 0.200 |
Why?
|
| Thromboembolism | 2 | 2019 | 987 | 0.190 |
Why?
|
| Fasting | 2 | 2018 | 1592 | 0.190 |
Why?
|
| Eligibility Determination | 2 | 2021 | 403 | 0.190 |
Why?
|
| Vasopressins | 2 | 2012 | 370 | 0.190 |
Why?
|
| Anemia | 3 | 2023 | 1503 | 0.190 |
Why?
|
| American Heart Association | 3 | 2020 | 1057 | 0.190 |
Why?
|
| Insulin | 3 | 2021 | 6582 | 0.190 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2020 | 35 | 0.190 |
Why?
|
| Reimbursement, Incentive | 2 | 2019 | 540 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4034 | 0.190 |
Why?
|
| Niacin | 1 | 2021 | 116 | 0.190 |
Why?
|
| Glucagon-Like Peptides | 1 | 2021 | 127 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 3922 | 0.190 |
Why?
|
| Enoxaparin | 1 | 2023 | 377 | 0.190 |
Why?
|
| Platelet Function Tests | 4 | 2016 | 270 | 0.190 |
Why?
|
| Outpatients | 4 | 2023 | 1487 | 0.190 |
Why?
|
| Physical Examination | 3 | 2021 | 1237 | 0.190 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 3508 | 0.190 |
Why?
|
| Enzyme Inhibitors | 3 | 2023 | 3799 | 0.190 |
Why?
|
| Acute Kidney Injury | 2 | 2024 | 1968 | 0.190 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 15078 | 0.180 |
Why?
|
| Receptors, Angiotensin | 1 | 2020 | 142 | 0.180 |
Why?
|
| Renal Artery | 1 | 2022 | 399 | 0.180 |
Why?
|
| Population Surveillance | 3 | 2021 | 2616 | 0.180 |
Why?
|
| Medication Adherence | 4 | 2020 | 2063 | 0.180 |
Why?
|
| Quality of Health Care | 5 | 2020 | 4369 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13693 | 0.180 |
Why?
|
| Logistic Models | 9 | 2023 | 13409 | 0.180 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 5321 | 0.180 |
Why?
|
| Monitoring, Ambulatory | 1 | 2023 | 355 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 2 | 2023 | 2535 | 0.180 |
Why?
|
| Orphan Drug Production | 1 | 2020 | 50 | 0.180 |
Why?
|
| Piperazines | 4 | 2015 | 2488 | 0.180 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2022 | 789 | 0.180 |
Why?
|
| North America | 3 | 2020 | 1249 | 0.180 |
Why?
|
| Benzoxazoles | 1 | 2020 | 77 | 0.170 |
Why?
|
| Thiophenes | 2 | 2015 | 589 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2021 | 1344 | 0.170 |
Why?
|
| Product Labeling | 1 | 2020 | 79 | 0.170 |
Why?
|
| Edema, Cardiac | 1 | 2018 | 18 | 0.170 |
Why?
|
| Research Report | 2 | 2019 | 355 | 0.170 |
Why?
|
| Matched-Pair Analysis | 3 | 2019 | 288 | 0.170 |
Why?
|
| Exercise | 3 | 2021 | 5615 | 0.170 |
Why?
|
| Chloroquine | 1 | 2020 | 279 | 0.170 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2019 | 371 | 0.160 |
Why?
|
| Heart Rate | 4 | 2023 | 4092 | 0.160 |
Why?
|
| Systole | 3 | 2020 | 958 | 0.160 |
Why?
|
| Uracil | 1 | 2020 | 165 | 0.160 |
Why?
|
| Survival Analysis | 7 | 2019 | 10252 | 0.160 |
Why?
|
| Women | 1 | 2020 | 230 | 0.160 |
Why?
|
| Drug Costs | 2 | 2023 | 1105 | 0.160 |
Why?
|
| Drug Resistance | 2 | 2019 | 1608 | 0.160 |
Why?
|
| Reimbursement Mechanisms | 2 | 2021 | 670 | 0.160 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 339 | 0.160 |
Why?
|
| Pyridones | 1 | 2023 | 711 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 3 | 2020 | 1831 | 0.160 |
Why?
|
| Databases, Factual | 7 | 2021 | 7730 | 0.160 |
Why?
|
| Risk | 5 | 2021 | 9688 | 0.160 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 217 | 0.160 |
Why?
|
| Mitral Valve Prolapse | 1 | 2020 | 231 | 0.160 |
Why?
|
| Uncertainty | 1 | 2023 | 735 | 0.160 |
Why?
|
| Uremia | 1 | 2018 | 200 | 0.150 |
Why?
|
| Health Care Costs | 2 | 2021 | 3208 | 0.150 |
Why?
|
| Coronavirus | 1 | 2020 | 158 | 0.150 |
Why?
|
| Advanced Practice Nursing | 1 | 2017 | 18 | 0.150 |
Why?
|
| Health Care Rationing | 1 | 2021 | 437 | 0.150 |
Why?
|
| Pericarditis | 1 | 2018 | 128 | 0.150 |
Why?
|
| Health Policy | 2 | 2021 | 2661 | 0.150 |
Why?
|
| Heart Injuries | 1 | 2019 | 210 | 0.150 |
Why?
|
| Hospitals, University | 1 | 2019 | 570 | 0.150 |
Why?
|
| Fee-for-Service Plans | 1 | 2022 | 694 | 0.150 |
Why?
|
| Italy | 2 | 2016 | 832 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 2019 | 243 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2020 | 559 | 0.140 |
Why?
|
| Emergencies | 2 | 2020 | 1170 | 0.140 |
Why?
|
| Liver Diseases | 2 | 2018 | 1253 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2021 | 8319 | 0.140 |
Why?
|
| Denmark | 3 | 2023 | 738 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2019 | 319 | 0.140 |
Why?
|
| Cost of Illness | 5 | 2021 | 1860 | 0.140 |
Why?
|
| Aldosterone | 1 | 2021 | 877 | 0.140 |
Why?
|
| Young Adult | 11 | 2023 | 56429 | 0.140 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 412 | 0.140 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 968 | 0.140 |
Why?
|
| Gout | 1 | 2023 | 573 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2013 | 11486 | 0.140 |
Why?
|
| Catheterization, Swan-Ganz | 2 | 2014 | 86 | 0.140 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 97 | 0.140 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 711 | 0.130 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2017 | 482 | 0.130 |
Why?
|
| Demography | 1 | 2020 | 1655 | 0.130 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2020 | 579 | 0.130 |
Why?
|
| Journalism, Medical | 1 | 2016 | 74 | 0.130 |
Why?
|
| New Zealand | 1 | 2016 | 355 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2018 | 6459 | 0.130 |
Why?
|
| Government Regulation | 2 | 2018 | 522 | 0.130 |
Why?
|
| Thailand | 1 | 2016 | 296 | 0.130 |
Why?
|
| Endocrinology | 1 | 2022 | 443 | 0.130 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2015 | 65 | 0.130 |
Why?
|
| Odds Ratio | 4 | 2020 | 9849 | 0.130 |
Why?
|
| Drug Tolerance | 1 | 2017 | 376 | 0.130 |
Why?
|
| Death | 1 | 2020 | 678 | 0.130 |
Why?
|
| Program Development | 2 | 2018 | 1316 | 0.130 |
Why?
|
| Muscular Diseases | 1 | 2019 | 555 | 0.130 |
Why?
|
| European Union | 1 | 2016 | 158 | 0.130 |
Why?
|
| Financing, Government | 1 | 2018 | 468 | 0.130 |
Why?
|
| Dyspepsia | 1 | 2016 | 116 | 0.130 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 426 | 0.130 |
Why?
|
| Osteoprotegerin | 1 | 2015 | 176 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2022 | 861 | 0.130 |
Why?
|
| Models, Organizational | 1 | 2018 | 574 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2020 | 850 | 0.130 |
Why?
|
| P-Selectin | 4 | 2015 | 601 | 0.120 |
Why?
|
| Hydrazones | 2 | 2013 | 102 | 0.120 |
Why?
|
| Alkaline Phosphatase | 2 | 2015 | 867 | 0.120 |
Why?
|
| Treatment Failure | 3 | 2016 | 2618 | 0.120 |
Why?
|
| Angiography | 1 | 2020 | 1639 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 2 | 2013 | 418 | 0.120 |
Why?
|
| Guideline Adherence | 3 | 2021 | 2265 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2020 | 970 | 0.120 |
Why?
|
| Peptic Ulcer | 1 | 2016 | 223 | 0.120 |
Why?
|
| Patients | 1 | 2021 | 900 | 0.120 |
Why?
|
| Access to Information | 1 | 2017 | 320 | 0.120 |
Why?
|
| Face | 1 | 2020 | 994 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 692 | 0.120 |
Why?
|
| Physical Fitness | 1 | 2018 | 732 | 0.120 |
Why?
|
| Intestinal Perforation | 1 | 2016 | 253 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 768 | 0.120 |
Why?
|
| Peer Review | 1 | 2016 | 209 | 0.120 |
Why?
|
| Osteopontin | 1 | 2015 | 294 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 2419 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 4 | 2024 | 5388 | 0.120 |
Why?
|
| Vancomycin | 1 | 2017 | 501 | 0.120 |
Why?
|
| Embolism, Air | 1 | 2014 | 111 | 0.120 |
Why?
|
| RANK Ligand | 1 | 2015 | 326 | 0.120 |
Why?
|
| Israel | 1 | 2016 | 796 | 0.120 |
Why?
|
| DNA, Viral | 1 | 2020 | 2227 | 0.120 |
Why?
|
| Blood Transfusion | 2 | 2018 | 1301 | 0.120 |
Why?
|
| Body Water | 1 | 2015 | 343 | 0.110 |
Why?
|
| Chicago | 2 | 2012 | 240 | 0.110 |
Why?
|
| Alanine Transaminase | 2 | 2013 | 592 | 0.110 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2020 | 1209 | 0.110 |
Why?
|
| Embolism | 1 | 2017 | 408 | 0.110 |
Why?
|
| Monocytes | 2 | 2013 | 2596 | 0.110 |
Why?
|
| Anticholesteremic Agents | 1 | 2021 | 979 | 0.110 |
Why?
|
| Blood Cell Count | 1 | 2014 | 403 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2017 | 705 | 0.110 |
Why?
|
| Second Messenger Systems | 1 | 2013 | 206 | 0.110 |
Why?
|
| Arrhythmia, Sinus | 1 | 2012 | 56 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 549 | 0.110 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2016 | 531 | 0.110 |
Why?
|
| Endocarditis, Bacterial | 1 | 2017 | 455 | 0.110 |
Why?
|
| Xanthines | 1 | 2013 | 121 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 1049 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2019 | 3914 | 0.110 |
Why?
|
| Leukocyte Count | 2 | 2013 | 1588 | 0.110 |
Why?
|
| Adolescent | 8 | 2023 | 85779 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 14723 | 0.110 |
Why?
|
| Urban Population | 1 | 2021 | 2022 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4933 | 0.110 |
Why?
|
| Multivariate Analysis | 5 | 2020 | 12244 | 0.110 |
Why?
|
| Sample Size | 1 | 2016 | 845 | 0.110 |
Why?
|
| Minority Groups | 1 | 2020 | 1221 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2020 | 3001 | 0.110 |
Why?
|
| Cyclic GMP | 1 | 2013 | 409 | 0.110 |
Why?
|
| Social Class | 1 | 2021 | 1997 | 0.110 |
Why?
|
| Illinois | 1 | 2012 | 119 | 0.110 |
Why?
|
| Blood Urea Nitrogen | 2 | 2024 | 191 | 0.110 |
Why?
|
| Government | 2 | 2023 | 165 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 281 | 0.110 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 423 | 0.100 |
Why?
|
| Health Facilities | 1 | 2017 | 572 | 0.100 |
Why?
|
| Sodium Channel Blockers | 1 | 2013 | 176 | 0.100 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 672 | 0.100 |
Why?
|
| Brazil | 1 | 2016 | 1270 | 0.100 |
Why?
|
| Hematocrit | 1 | 2013 | 636 | 0.100 |
Why?
|
| Eye Movements | 1 | 2015 | 507 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1257 | 0.100 |
Why?
|
| Acetanilides | 1 | 2013 | 168 | 0.100 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 952 | 0.100 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 1354 | 0.100 |
Why?
|
| Forecasting | 2 | 2018 | 2951 | 0.100 |
Why?
|
| Piperidines | 1 | 2020 | 1602 | 0.100 |
Why?
|
| Cell Size | 2 | 2010 | 643 | 0.100 |
Why?
|
| Pyridazines | 1 | 2013 | 202 | 0.100 |
Why?
|
| Propensity Score | 3 | 2012 | 1781 | 0.100 |
Why?
|
| Sodium, Dietary | 1 | 2015 | 418 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2018 | 1547 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 1607 | 0.100 |
Why?
|
| Colchicine | 2 | 2023 | 244 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 680 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2015 | 1460 | 0.090 |
Why?
|
| Diabetic Angiopathies | 3 | 2021 | 818 | 0.090 |
Why?
|
| Health Surveys | 1 | 2021 | 4036 | 0.090 |
Why?
|
| Arachidonic Acid | 2 | 2010 | 434 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 1213 | 0.090 |
Why?
|
| Blood Coagulation Disorders | 1 | 2013 | 337 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 687 | 0.090 |
Why?
|
| Coronary Stenosis | 2 | 2014 | 834 | 0.090 |
Why?
|
| Animals | 11 | 2022 | 168768 | 0.090 |
Why?
|
| Rural Population | 1 | 2021 | 2207 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2018 | 3309 | 0.090 |
Why?
|
| Electrophysiology | 1 | 2013 | 1308 | 0.090 |
Why?
|
| Cholesterol | 3 | 2021 | 2919 | 0.090 |
Why?
|
| Polypharmacy | 2 | 2023 | 294 | 0.090 |
Why?
|
| New York | 2 | 2023 | 886 | 0.090 |
Why?
|
| Protons | 1 | 2015 | 1127 | 0.090 |
Why?
|
| Aortic Valve | 1 | 2020 | 1924 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 980 | 0.090 |
Why?
|
| Seasons | 1 | 2016 | 1493 | 0.090 |
Why?
|
| Head | 1 | 2015 | 880 | 0.090 |
Why?
|
| Depression | 2 | 2020 | 7759 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2760 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 13991 | 0.090 |
Why?
|
| Blood Proteins | 2 | 2020 | 1124 | 0.090 |
Why?
|
| Myocarditis | 1 | 2017 | 771 | 0.090 |
Why?
|
| Pneumonia | 1 | 2021 | 2133 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2019 | 3531 | 0.080 |
Why?
|
| Health Care Reform | 1 | 2018 | 1261 | 0.080 |
Why?
|
| Recurrence | 3 | 2016 | 8340 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2019 | 1591 | 0.080 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2162 | 0.080 |
Why?
|
| Eosinophils | 1 | 2013 | 955 | 0.080 |
Why?
|
| Algorithms | 2 | 2020 | 13882 | 0.080 |
Why?
|
| Poverty | 1 | 2020 | 2660 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 19905 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 1400 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2018 | 1140 | 0.080 |
Why?
|
| Public Health | 1 | 2020 | 2602 | 0.080 |
Why?
|
| Self Efficacy | 2 | 2023 | 615 | 0.080 |
Why?
|
| Drug Substitution | 2 | 2021 | 281 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 2269 | 0.070 |
Why?
|
| Equipment Design | 1 | 2015 | 3582 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 1332 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2019 | 21748 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 215 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 1888 | 0.070 |
Why?
|
| Sweden | 2 | 2021 | 1341 | 0.070 |
Why?
|
| Triglycerides | 2 | 2012 | 2453 | 0.070 |
Why?
|
| Albumins | 2 | 2023 | 568 | 0.070 |
Why?
|
| Mast Cells | 1 | 2013 | 1544 | 0.070 |
Why?
|
| Statistics as Topic | 3 | 2021 | 2373 | 0.070 |
Why?
|
| Protein Precursors | 2 | 2020 | 1154 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 6896 | 0.060 |
Why?
|
| Phenotype | 3 | 2021 | 16367 | 0.060 |
Why?
|
| Sodium-Glucose Transport Proteins | 1 | 2024 | 12 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 2278 | 0.060 |
Why?
|
| Echocardiography, Doppler | 2 | 2019 | 935 | 0.060 |
Why?
|
| Hospital Costs | 2 | 2021 | 985 | 0.060 |
Why?
|
| Health Status Disparities | 3 | 2021 | 1796 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 3508 | 0.060 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 1519 | 0.060 |
Why?
|
| Hypovolemia | 1 | 2023 | 45 | 0.060 |
Why?
|
| Primary Prevention | 2 | 2021 | 1167 | 0.050 |
Why?
|
| Caffeine | 1 | 2007 | 699 | 0.050 |
Why?
|
| Catheter Ablation | 2 | 2016 | 2758 | 0.050 |
Why?
|
| Growth Differentiation Factors | 1 | 2023 | 98 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2023 | 1184 | 0.050 |
Why?
|
| Coronary Disease | 2 | 2012 | 6077 | 0.050 |
Why?
|
| Sympathectomy | 1 | 2022 | 89 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2725 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 8642 | 0.050 |
Why?
|
| Lipid Regulating Agents | 1 | 2021 | 24 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 4257 | 0.050 |
Why?
|
| Massachusetts | 3 | 2019 | 8662 | 0.050 |
Why?
|
| Electronics | 1 | 2023 | 322 | 0.050 |
Why?
|
| Health Care Coalitions | 1 | 2021 | 35 | 0.050 |
Why?
|
| Denervation | 1 | 2022 | 278 | 0.050 |
Why?
|
| Retreatment | 2 | 2014 | 610 | 0.050 |
Why?
|
| Pyridines | 1 | 2013 | 2825 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2013 | 683 | 0.050 |
Why?
|
| India | 3 | 2019 | 2197 | 0.050 |
Why?
|
| Michigan | 1 | 2021 | 350 | 0.050 |
Why?
|
| Pain | 1 | 2016 | 4988 | 0.050 |
Why?
|
| Internationality | 2 | 2019 | 1002 | 0.050 |
Why?
|
| Esters | 1 | 2021 | 210 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2021 | 4222 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 4459 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2008 | 1036 | 0.050 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 127 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2023 | 692 | 0.050 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 74 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 1 | 2021 | 298 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7658 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 141 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2023 | 670 | 0.040 |
Why?
|
| Thromboxane B2 | 2 | 2010 | 152 | 0.040 |
Why?
|
| Hemodilution | 1 | 2019 | 114 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2020 | 328 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 10183 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2020 | 393 | 0.040 |
Why?
|
| Isosorbide Dinitrate | 1 | 2019 | 34 | 0.040 |
Why?
|
| Catheters | 1 | 2022 | 425 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 2023 | 591 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 20824 | 0.040 |
Why?
|
| Accreditation | 1 | 2022 | 452 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2023 | 1159 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 7182 | 0.040 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 2029 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2012 | 3680 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2022 | 1590 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 315 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 6364 | 0.040 |
Why?
|
| Adenosine Diphosphate | 2 | 2010 | 425 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2020 | 437 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2020 | 227 | 0.040 |
Why?
|
| Sympathetic Nervous System | 1 | 2020 | 513 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2021 | 550 | 0.040 |
Why?
|
| Linear Models | 2 | 2018 | 5953 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2014 | 1461 | 0.040 |
Why?
|
| Insurance, Health | 2 | 2021 | 2494 | 0.040 |
Why?
|
| Galectins | 1 | 2020 | 268 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 114 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2023 | 6542 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 2001 | 435 | 0.040 |
Why?
|
| Procollagen | 1 | 2017 | 185 | 0.040 |
Why?
|
| Poisoning | 1 | 2018 | 249 | 0.040 |
Why?
|
| Prejudice | 1 | 2021 | 570 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2023 | 1868 | 0.030 |
Why?
|
| ROC Curve | 2 | 2015 | 3528 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2021 | 996 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 3771 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 1180 | 0.030 |
Why?
|
| Patient Admission | 2 | 2014 | 1380 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 7785 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2015 | 79 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2023 | 1036 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 1073 | 0.030 |
Why?
|
| Placebos | 1 | 2019 | 1676 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2015 | 209 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2307 | 0.030 |
Why?
|
| Platelet Count | 2 | 2008 | 780 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2020 | 853 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 1151 | 0.030 |
Why?
|
| Brain Death | 1 | 2018 | 348 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 2019 | 517 | 0.030 |
Why?
|
| Cholesterol, LDL | 2 | 2021 | 2355 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2019 | 926 | 0.030 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2017 | 488 | 0.030 |
Why?
|
| Pacemaker, Artificial | 1 | 2020 | 816 | 0.030 |
Why?
|
| Models, Economic | 1 | 2018 | 712 | 0.030 |
Why?
|
| Nicaragua | 1 | 2013 | 27 | 0.030 |
Why?
|
| China | 1 | 2020 | 2245 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2715 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2015 | 153 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2020 | 956 | 0.030 |
Why?
|
| Drug Industry | 1 | 2020 | 746 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2018 | 577 | 0.030 |
Why?
|
| Rome | 1 | 2013 | 28 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2021 | 849 | 0.030 |
Why?
|
| Chest Pain | 1 | 2020 | 1114 | 0.030 |
Why?
|
| Europe, Eastern | 1 | 2012 | 75 | 0.030 |
Why?
|
| Psychometrics | 1 | 2022 | 3003 | 0.030 |
Why?
|
| After-Hours Care | 1 | 2014 | 102 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2019 | 1127 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2013 | 176 | 0.030 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 128 | 0.030 |
Why?
|
| Vitamins | 1 | 2021 | 1623 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2019 | 2110 | 0.030 |
Why?
|
| South America | 1 | 2012 | 181 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 964 | 0.030 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 112 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 3252 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 609 | 0.030 |
Why?
|
| Epidemics | 1 | 2018 | 523 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2022 | 2585 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 639 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Mexico | 1 | 2013 | 689 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 1862 | 0.020 |
Why?
|
| Editorial Policies | 1 | 2016 | 451 | 0.020 |
Why?
|
| Dopamine | 1 | 2018 | 1591 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 1438 | 0.020 |
Why?
|
| Patient Participation | 1 | 2020 | 1457 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2015 | 950 | 0.020 |
Why?
|
| Hyponatremia | 1 | 2014 | 298 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2010 | 143 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1655 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 1265 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2013 | 394 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2012 | 528 | 0.020 |
Why?
|
| Heart Atria | 1 | 2016 | 1356 | 0.020 |
Why?
|
| Endarterectomy, Carotid | 1 | 2015 | 546 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2019 | 2488 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2013 | 5974 | 0.020 |
Why?
|
| Critical Illness | 1 | 2023 | 2670 | 0.020 |
Why?
|
| Radiography | 2 | 2013 | 7023 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2020 | 1887 | 0.020 |
Why?
|
| Fever | 1 | 2017 | 1616 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 35425 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1178 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 1453 | 0.020 |
Why?
|
| Receptors, Thromboxane | 1 | 2008 | 31 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2021 | 3296 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 1364 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 3020 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2008 | 104 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 2013 | 792 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 501 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2013 | 764 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2015 | 1184 | 0.020 |
Why?
|
| Hand Joints | 1 | 2008 | 53 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2014 | 1572 | 0.020 |
Why?
|
| Vitamin D | 1 | 2021 | 3224 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2017 | 3203 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1900 | 0.020 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2007 | 124 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2010 | 894 | 0.020 |
Why?
|
| Receptors, Thrombin | 1 | 2007 | 131 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 669 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2008 | 411 | 0.020 |
Why?
|
| Texas | 1 | 2007 | 391 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2971 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9312 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2013 | 19233 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2016 | 2926 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2010 | 1728 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3265 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 6755 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 2132 | 0.010 |
Why?
|
| Models, Biological | 1 | 2020 | 9584 | 0.010 |
Why?
|
| Smoking | 1 | 2021 | 8987 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 3778 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2007 | 1794 | 0.010 |
Why?
|
| Mass Screening | 1 | 2019 | 5253 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6366 | 0.010 |
Why?
|
| Apolipoproteins A | 1 | 2001 | 94 | 0.010 |
Why?
|
| Reference Values | 1 | 2008 | 4982 | 0.010 |
Why?
|
| Apolipoprotein B-100 | 1 | 2001 | 148 | 0.010 |
Why?
|
| Students, Medical | 1 | 2013 | 1862 | 0.010 |
Why?
|
| Collagen | 1 | 2008 | 2688 | 0.010 |
Why?
|
| Apolipoproteins B | 1 | 2001 | 374 | 0.010 |
Why?
|
| Lung | 1 | 2017 | 9857 | 0.010 |
Why?
|
| Osteoarthritis, Knee | 1 | 2008 | 1222 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2001 | 1683 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9724 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1730 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2001 | 1813 | 0.010 |
Why?
|
| Child | 1 | 2019 | 77709 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 17446 | 0.000 |
Why?
|